Plant-based pain relief: the research moving the field forward

4 minute read · Drakensberg Cannabis Journal

For people living with persistent pain, the prospect of another useful option is deeply practical. Recent trials are bringing that possibility into sharper focus.

Pain can shrink a person’s day. A walk becomes shorter, a night’s rest becomes fragmented, and ordinary tasks begin to require negotiation. When existing treatments provide incomplete relief or bring difficult side effects, interest in plant-derived approaches is understandable.

The most useful research takes that interest seriously. It asks whether a defined preparation can improve an outcome that matters, and whether its benefits compare favourably with its drawbacks. Several recent trials have moved that conversation beyond broad claims about “natural relief”.

A major cannabis trial in persistent back pain

A 2025 phase 3 trial enrolled 820 adults with chronic low back pain. Over its blinded 12-week treatment phase, the standardised full-spectrum extract VER-01 reduced pain by an average of 1.9 points on a 0–10 scale, about 0.6 points more than placebo. Adverse events occurred more often with the extract: 83.3% versus 67.3%. The later withdrawal phase did not meet its primary endpoint. The Nature Medicine paper reports a meaningful research advance, with a modest average advantage over placebo.

A separate 2025 randomised trial compared VER-01 with opioid treatment in 384 adults. The risk of constipation was lower with VER-01, with a relative risk of 0.25. Average pain and sleep outcomes across six months favoured the extract modestly, although key comparisons at week 27 were not statistically significant. The trial was open-label and manufacturer-funded, and the result applies to this particular preparation. Read the head-to-head study.

These are important questions to see tested directly. Better symptom control is only part of a treatment’s value; tolerability can also determine whether a person finds it workable in daily life. Neither trial establishes that all cannabis oils outperform opioids or that changing treatment without clinical support is safe.

Useful relief is personal: less pain, more function, and a treatment a person can actually live with.

Topical CBD: small trials with intriguing signals

In a 2022 crossover trial of 18 people with thumb basal-joint arthritis, a CBD preparation in shea butter improved reported pain and disability compared with shea butter alone. Grip strength and range-of-motion measurements were similar. The trial gives a small but interesting human signal for a local preparation.

Another small trial, published in 2020, investigated topical CBD oil in 29 people with peripheral neuropathy. Researchers found reductions in intense and sharp pain and in cold and itchy sensations compared with placebo. That study supports further investigation rather than a universal neuropathy claim. A 2024 pilot trial in 40 people with chemotherapy-induced neuropathy did not show benefit from its CBD-isolate cream. The contrasting result helps identify where the questions remain open.

An older botanical comparison worth knowing

Arnica has also been investigated clinically. A 2007 double-blind trial compared a defined arnica gel with ibuprofen gel in 204 people with hand osteoarthritis. Over 21 days, improvements in pain and hand function were similar, meeting the study’s non-inferiority conclusion. This concerned a phytotherapeutic arnica extract, not a homeopathic dilution, and it did not include a placebo group. Widrig and colleagues’ trial is a useful example of a botanical preparation being compared directly with a conventional topical treatment.

A future with more considered choices

The promising direction is not a single plant replacing every pain medicine. It is a larger, better-understood range of options, informed by condition-specific evidence and by the outcomes people care about. A topical approach, an oral extract and a rehabilitation plan answer different needs.

These studies did not test Drakensberg Cannabis products. They explain why the ingredients interest us, and why thoughtful preparation matters. If a botanical option may allow someone to reduce a prescribed medicine, that change should be planned with the prescriber; abrupt changes can create problems unrelated to the new treatment’s potential.

There is room for real optimism here. The field is asking more ambitious questions—and increasingly has human results worth discussing.